{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007037","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.501240+00:00","generated_at":"2026-06-18T06:57:06.571463+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Clearside Biomedical reports Q4 net loss of $9.7M; Phase 2b wet AMD trial on track for Q2 2023","bullets":["Q4 net loss $9.7M ($0.16/share) vs net income $18.7M ($0.31/share) in Q4 2021 on lower license revenue.","Full-year 2022 net loss $32.9M ($0.55/share) vs net income $376K ($0.01/share) in 2021.","Cash $48.3M at Dec 31, 2022; runway into Q2 2024.","Phase 2b ODYSSEY trial of CLS-AX in wet AMD to start Q2 2023; comparator arm adjusted to on-label aflibercept per FDA draft guidance.","Bausch + Lomb trained over 1,000 retinal physicians on SCS Microinjector for XIPERE."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007037","json":"https://secwatch.observer/filing/0000950170-23-007037.json","markdown":"https://secwatch.observer/filing/0000950170-23-007037.md","text":"https://secwatch.observer/filing/0000950170-23-007037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023007037/0000950170-23-007037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023007037/clsd-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T06:57:06.571463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"200c89e14516269525204b0da1d3fde6e12e7a55","claim":"Clearside Biomedical, Inc. reported Year ended December 31, 2022 results: revenue $1.3 million, net income Net loss of $32.9 million, EPS $0.55 per share.","evidence_excerpt":"Clearside’s license and other revenue for the year ended December 31, 2022, was $1.3 million, compared to $29.6 million for the year ended December 31, 2021. The $28.2 million decrease was primarily attributable to one-time milestone payments received from XIPERE licensing partners in 2021. Cost of goods sold for the year ended December 31, 2022, was $204,000, compared to $0 for the year ended December 31, 2021. This increase was related to sales of Clearside’s SCS Microinjector. Research and development expenses for the year ended December 31, 2022, were $19.6 million, compared to $18.5 million for the year ended December 31, 2021. The $1.1 million increase was primarily attributable to CLS-AX program costs. General and administrative expenses for the year ended December 31, 2022, were $11.8 million, compared to $11.7 million for the year ended December 31, 2021. Net loss for the year ended December 31, 2022, was $32.9 million, or $0.55 per share of common stock, compared to net incom","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023007037/0000950170-23-007037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Year ended December 31, 2022"},{"label":"Revenue","value":"$1.3 million"},{"label":"Net income","value":"Net loss of $32.9 million"},{"label":"EPS","value":"$0.55 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9448b33834804d8b8ee6b2905ebf9e5187efe532","claim":"Clearside Biomedical, Inc. reported Fourth quarter 2022 results: revenue $330,000, net income Net loss of $9.7 million, EPS $0.16 per share.","evidence_excerpt":"Clearside’s license and other revenue for the fourth quarter of 2022 was $330,000, compared to $25.7 million for the fourth quarter of 2021. The $25.4 million decrease was primarily attributable to one-time milestone payments received from XIPERE licensing partners in the fourth quarter of 2021. Cost of goods sold for the fourth quarter of 2022 was $204,000, compared to $0 for the fourth quarter of 2021. This increase was related to sales of Clearside’s SCS Microinjector. Research and development expenses for the fourth quarter of 2022 were $5.0 million, compared to $3.8 million for the fourth quarter of 2021. The $1.2 million increase was primarily attributable to preclinical research program costs. General and administrative expenses for the fourth quarter of 2022 were $3.2 million, compared to $3.1 million for the fourth quarter of 2021. Net loss for the fourth quarter of 2022 was $9.7 million, or $0.16 per share of common stock, compared to net income of $18.7 million, or $0.31 per","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023007037/0000950170-23-007037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth quarter 2022"},{"label":"Revenue","value":"$330,000"},{"label":"Net income","value":"Net loss of $9.7 million"},{"label":"EPS","value":"$0.16 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}